Latest Breaking News On - Sairiyo therapeutics inc - Page 2 : comparemela.com

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

TORONTO, April 18, 2024 PharmaTher Holdings Ltd. , a specialty pharmaceutical company, today announced receipt of a Complete Response Letter for its Priority Original Abbreviated New Drug.

Fabio chianelliDrug administrationHealth canadaRegulation services providerNeither the canadian securities exchangeCompany or pharmatherSairiyo therapeutics incPharmather holdings ltdRisk factors in companyMother holdingsComplete response letterGeneric drug user fee amendmentsCanadian securities exchangePharmather holdings

PharmaDrug Appoints Current Board Member Dr David Kideckel as Chairman

PharmaDrug Inc. , a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously.

United statesRobertj steenRobert steenDavid kideckelSecuredose synthetics incAustralian federal government researchPharmather holdings ltdNewsfile corpPharmadrug incUniversity of toronto institute medical scienceAlexion pharmaceuticalsUniversity of toronto rotman school managementJohnson incFounder of the kideckel advisory group incSairiyo therapeutics incKideckel advisory group inc

PharmaTher s Sairiyo Therapeutics Inc Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia

PharmaTher s Sairiyo Therapeutics Inc Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFabio chianelliCompany or pharmatherAustralia therapeutic goods administrationDrug administrationRisk factors in companyRegulation services providerSairiyo therapeutics incPharmdrug incNeither the canadian securities exchangeAustralian federal government researchPharmadrug incPharmather holdings ltdMother holdingsSairiyo therapeuticsAustralian federal government

PharmaTher s Sairiyo Therapeutics Inc Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia -February 21, 2024 at 09:31 am EST

TORONTO, Feb. 21, 2024 PharmaTher Holdings Ltd. , a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. , a company that is forty-nine percent owned by PharmaTher and.

United statesFabio chianelliAustralia therapeutic goods administrationDrug administrationPharmdrug incRisk factors in companyNeither the canadian securities exchangePharmadrug incRegulation services providerPharmather holdings ltdSairiyo therapeutics incCompany or pharmatherAustralian federal government researchMother holdingsSairiyo therapeuticsAustralian federal government

PharmaTher s Sairiyo Therapeutics Inc Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia

PharmaTher s Sairiyo Therapeutics Inc Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesBarbara shecterGabriel friedmanJoe oconnorMichael roseFabio chianelliTiff macklemPharmdrug incNeither the canadian securities exchangeRisk factors in companyAustralia therapeutic goods administrationAdvances clinical development of patented reformulated cepharanthinePharmadrug incNational postPharmather sairiyo therapeutics inc